Delagrange P - Search Results

1

Therapeutic perspectives for melatonin agonists and antagonists.

Delagrange P, Atkinson J, Boutin JA, Casteilla L, Lesieur D, Misslin R, Pellissier S, Pénicaud L, Renard P. Delagrange P, et al. J Neuroendocrinol. 2003 Apr;15(4):442-8. doi: 10.1046/j.1365-2826.2003.01016.x. J Neuroendocrinol. 2003. PMID: 12622848 Review.

2

Therapeutic potential of melatonin ligands.

Delagrange P, Boutin JA. Delagrange P, et al. Chronobiol Int. 2006;23(1-2):413-8. doi: 10.1080/07420520500464387. Chronobiol Int. 2006. PMID: 16687314 Review.

3

Synthesis and structure-affinity-activity relationships of novel benzofuran derivatives as MT(2) melatonin receptor selective ligands.

Wallez V, Durieux-Poissonnier S, Chavatte P, Boutin JA, Audinot V, Nicolas JP, Bennejean C, Delagrange P, Renard P, Lesieur D. Wallez V, et al. Among authors: delagrange p. J Med Chem. 2002 Jun 20;45(13):2788-800. doi: 10.1021/jm0005252. J Med Chem. 2002. PMID: 12061881

4

New selective ligands of human cloned melatonin MT1 and MT2 receptors.

Audinot V, Mailliet F, Lahaye-Brasseur C, Bonnaud A, Le Gall A, Amossé C, Dromaint S, Rodriguez M, Nagel N, Galizzi JP, Malpaux B, Guillaumet G, Lesieur D, Lefoulon F, Renard P, Delagrange P, Boutin JA. Audinot V, et al. Among authors: delagrange p. Naunyn Schmiedebergs Arch Pharmacol. 2003 Jun;367(6):553-61. doi: 10.1007/s00210-003-0751-2. Epub 2003 May 23. Naunyn Schmiedebergs Arch Pharmacol. 2003. PMID: 12764576

5

Molecular tools to study melatonin pathways and actions.

Boutin JA, Audinot V, Ferry G, Delagrange P. Boutin JA, et al. Among authors: delagrange p. Trends Pharmacol Sci. 2005 Aug;26(8):412-9. doi: 10.1016/j.tips.2005.06.006. Trends Pharmacol Sci. 2005. PMID: 15992934 Review.

6

Synthesis and structure-activity relationships of novel naphthalenic and bioisosteric related amidic derivatives as melatonin receptor ligands.

Leclerc V, Fourmaintraux E, Depreux P, Lesieur D, Morgan P, Howell HE, Renard P, Caignard DH, Pfeiffer B, Delagrange P, Guardiola-Lemaître B, Andrieux J. Leclerc V, et al. Among authors: delagrange p. Bioorg Med Chem. 1998 Oct;6(10):1875-87. doi: 10.1016/s0968-0896(98)00147-3. Bioorg Med Chem. 1998. PMID: 9839017

7

Antagonistic effects of S 22153, a new mt1 and MT2 receptor ligand, on the neophobia-reducing properties of melatonin in BALB/c mice.

Kopp C, Vogel E, Rettori MC, Delagrange P, Renard P, Lesieur D, Misslin R. Kopp C, et al. Among authors: delagrange p. Pharmacol Biochem Behav. 1999 Sep;64(1):131-6. doi: 10.1016/s0091-3057(99)00071-4. Pharmacol Biochem Behav. 1999. PMID: 10495007

8

Screening of ligand binding on melatonin receptor using non-peptide combinatorial libraries.

Boutin JA, Lahaye C, Pegurier C, Nicolas JP, Fauchere JL, Langlois M, Renard P, Delagrange P, Canet E. Boutin JA, et al. Among authors: delagrange p. J Recept Signal Transduct Res. 2000 Jan;20(1):105-18. doi: 10.3109/10799890009150040. J Recept Signal Transduct Res. 2000. PMID: 10711500

9

Regulation of emotional behaviour by day length in mice: implication of melatonin.

Kopp C, Vogel E, Rettori MC, Delagrange P, Renard P, Lesieur D, Misslin R. Kopp C, et al. Among authors: delagrange p. Behav Pharmacol. 1999 Dec;10(8):747-52. doi: 10.1097/00008877-199912000-00006. Behav Pharmacol. 1999. PMID: 10780290

10

Effect of melatonin on motility pattern of small intestine in rats and its inhibition by melatonin receptor antagonist S 22153.

Merle A, Delagrange P, Renard P, Lesieur D, Cuber JC, Roche M, Pellissier S. Merle A, et al. Among authors: delagrange p. J Pineal Res. 2000 Sep;29(2):116-24. doi: 10.1034/j.1600-079x.2000.290208.x. J Pineal Res. 2000. PMID: 10981825

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

208 results

Search Page